Merck & Co – known as MSD outside of the US and Canada – has announced that it will be expanding its respiratory diseases ...

Lung conditions, like asthma and chronic obstructive pulmonary disease, are more common in women than men. Stephanie Harris ...

Arexvy is currently approved to prevent lower respiratory tract disease (LRTD) caused by RSV in individuals aged 60 years and older, and those 50 to 59 years of age who are at increased risk for LRTD ...

Each year, almost 200,000 adults 65 and older are hospitalized due to RSV, and an estimated 14,000 of those cases result in ...

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

Pharmaceutical giant Merck is buying Verona Pharma, a company that concentrates its efforts on respiratory diseases, in an ...

Merck said the deal is valued at $107 per ADS, a 23% premium to Verona’s closing price yesterday.

The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.